|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li JY, Shi J, Sang JF, Yao YZ, Wang XC and
Su L: Role of survivin in the pathogenesis of papillary thyroid
carcinoma. Genet Mol Res. 14:15102–15111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrada CC, Godoy CC, Martínez AA and
García BH: Papillary thyroid cancer: Case reports of four family
cases. Rev Chil Pediatr. 85:351–358. 2014.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hodak S, Tuttle RM, Maytal G, Nikiforov YE
and Randolph G: Changing the cancer diagnosis: The case of
follicular variant of papillary thyroid cancer-primum non nocere
and NIFTP. Thyroid. 26:869–881. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liang H, Zhong Y, Luo Z, Huang Y, Lin H,
Luo M, Zhan S, Xie K, Ma Y and Li QQ: Assessment of biomarkers for
clinical diagnosis of papillary thyroid carcinoma with distant
metastasis. Int J Biol Markers. 25:38–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin L, Chen E, Dong S, Cai Y, Zhang X,
Zhou Y, Zeng R, Yang F, Pan C, Liu Y, et al: BRAF and TERT promoter
mutations in the aggressiveness of papillary thyroid carcinoma: A
study of 653 patients. Oncotarget. 7:18346–18355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z,
Zhou Y and Xing M: Characterization of the novel tumor-suppressor
gene CCDC67 in papillary thyroid carcinoma. Oncotarget.
7:5830–5841. 2016.PubMed/NCBI
|
|
8
|
Pauli A, Rinn JL and Schier AF: Non-coding
RNAs as regulators of embryogenesis. Nat Rev Genet. 12:136–149.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng L, Zhou R, Chen M, Feng L and Li H:
MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit
cell proliferation, migration and invasion in papillary thyroid
carcinoma. Mol Med Rep. 16:2217–2224. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J, Li Q, Li R, Ren P and Dong S:
MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by
targeting PIK3CA. Am J Cancer Res. 7:148–158. 2017.PubMed/NCBI
|
|
11
|
Stephen JK, Chen KM, Merritt J, Chitale D,
Divine G and Worsham MJ: Methylation markers for early detection
and differentiation of follicular thyroid cancer subtypes. Cancer
Clin Oncol. 4:1–12. 2015.PubMed/NCBI
|
|
12
|
Iacobas DA, Tuli NY, Iacobas S, Rasamny
JK, Moscatello A, Geliebter J and Tiwari RK: Gene master regulators
of papillary and anaplastic thyroid cancers. Oncotarget.
9:2410–2424. 2017.PubMed/NCBI
|
|
13
|
Liyanarachchi S, Li W, Yan P, Bundschuh R,
Brock P, Senter L, Ringel MD, de la Chapelle A and He H:
Genome-wide expression screening discloses long noncoding RNAs
involved in thyroid carcinogenesis. J Clin Endocrinol Metab.
101:4005–4013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Minna E, Romeo P, Dugo M, De Cecco L,
Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, et
al: miR-451a is underexpressed and targets AKT/mTOR pathway in
papillary thyroid carcinoma. Oncotarget. 7:12731–12747. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beltrami CM, Dos Reis MB, Barros-Filho MC,
Marchi FA, Kuasne H, Pinto CAL, Ambatipudi S, Herceg Z, Kowalski LP
and Rogatto SR: Integrated data analysis reveals potential drivers
and pathways disrupted by DNA methylation in papillary thyroid
carcinomas. Clin Epigenetics. 9:452017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bisarro Dos Reis M, Barros-Filho MC,
Marchi FA, Beltrami CM, Kuasne H, Pinto CAL, Ambatipudi S, Herceg
Z, Kowalski LP and Rogatto SR: Prognostic classifier based on
genome-wide DNA methylation profiling in well-differentiated
thyroid tumors. J Clin Endocrinol Metab. 102:4089–4099. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for Annotation,
Visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanehisa M, Goto S, Sato Y, Furumichi M
and Tanabe M: KEGG: Kyoto encyclopedia of genes and genomes.
Nucleic Acids Res. 27:29–34. 2000.
|
|
19
|
D'Eustachio P: Reactome knowledgebase of
human biological pathways and processes. Methods Mol Biol.
694:49–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ahmadi A, Khansarinejad B, Hosseinkhani S,
Ghanei M and Mowla SJ: miR-199a-5p and miR-495 target GRP78 within
UPR pathway of lung cancer. Gene. 620:15–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fehm T, Schultz S, Bartsch H, Petat-Dutter
K, Kahlert S, Sotlar K, Niederacher D and Neubauer H: Abstract
P4-09-09: Verification of the breast cancer progression-associated
miRNA hsa-miR-199a-5p using NanoString® platform. Cancer
Res. 76 (4 Suppl):2016.
|
|
23
|
Ma S, Jia W and Ni S: miR-199a-5p inhibits
the progression of papillary thyroid carcinoma by targeting SNAI1.
Biochem Biophys Res Commun. 497:181–186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun D, Han S, Liu C, Zhou R, Sun W, Zhang
Z and Qu J: Microrna-199a-5p functions as a tumor suppressor via
suppressing connective tissue growth factor (CTGF) in follicular
thyroid carcinoma. Med Sci Monit. 22:1210–1217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung SY, Park ES, Park SY, Song JY and
Ryu HS: CXC motif ligand 12 as a novel diagnostic marker for
papillary thyroid carcinoma. Head Neck. 36:1005–1012. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang S, Wang Y, Chen M, Sun L, Han J,
Elena VK and Qiao H: CXCL12 methylation-mediated epigenetic
regulation of gene expression in papillary thyroid carcinoma. Sci
Rep. 7:440332017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arnaldi LA, Borra RC, Maciel RM and
Cerutti JM: Gene expression profiles reveal that DCN, DIO1, and
DIO2 are underexpressed in benign and malignant thyroid tumors.
Thyroid. 15:210–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jarzab B, Wiench M, Fujarewicz K, Simek K,
Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E,
Lange D, et al: Gene expression profile of papillary thyroid
cancer: Sources of variability and diagnostic implications. Cancer
Res. 65:1587–1597. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Watson PH, Chia SK, Wykoff CC, Han C, Leek
RD, Sly WS, Gatter KC, Ratcliffe P and Harris AL: Carbonic
anhydrase XII is a marker of good prognosis in invasive breast
carcinoma. Br J Cancer. 88:1065–1070. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoo CW, Nam BH, Kim JY, Shin HJ, Lim H,
Lee S, Lee SK, Lim MC and Song YJ: Carbonic anhydrase XII
expression is associated with histologic grade of cervical cancer
and superior radiotherapy outcome. Radiat Oncol. 5:1012010.
View Article : Google Scholar : PubMed/NCBI
|
